|
2023 Journal Article Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetesLeung, Sherman S., Lenchik, Nataliya, Mathews, Clayton, Pugliese, Alberto, McCarthy, Domenica A., Le Bagge, Selena, Ewing, Adam, Harris, Mark, Radford, Kristen J., Borg, Danielle J., Gerling, Ivan and Forbes, Josephine M. (2023). Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes. Scientific Reports, 13 (1) 12948, 1-15. doi: 10.1038/s41598-023-39243-x |
|
2022 Journal Article Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T CellsLeung, Sherman S., Borg, Danielle J., McCarthy, Domenica A., Boursalian, Tamar E., Cracraft, Justen, Zhuang, Aowen, Fotheringham, Amelia K., Flemming, Nicole, Watkins, Thomas, Miles, John J., Groop, Per-Henrik, Scheijen, Jean L., Schalkwijk, Casper G., Steptoe, Raymond J., Radford, Kristen J., Knip, Mikael and Forbes, Josephine M. (2022). Soluble RAGE Prevents Type 1 Diabetes Expanding Functional Regulatory T Cells. Diabetes, 71 (9), 1994-2008. doi: 10.2337/db22-0177 |
|
2021 Journal Article Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental modelBorg, Danielle J., Faridi, Pouya, Giam, Kai Lin, Reeves, Peta, Fotheringham, Amelia K., McCarthy, Domenica A., Leung, Sherman, Ward, Micheal S., Harcourt, Brooke E., Ayala, Rochelle, Scheijen, Jean L., Briskey, David, Dudek, Nadine L., Schalkwijk, Casper G., Steptoe, Raymond, Purcell, Anthony W. and Forbes, Josephine M. (2021). Short duration alagebrium chloride therapy prediabetes does not inhibit progression to autoimmune diabetes in an experimental model. Metabolites, 11 (7) 426, 1-21. doi: 10.3390/metabo11070426 |
|
2021 Journal Article Advanced glycation end products as predictors of renal function in youth with type 1 diabetesForbes, Josephine M., Le Bagge, Selena, Righi, Samuel, Fotheringham, Amelia K., Gallo, Linda A., McCarthy, Domenica A., Leung, Sherman, Baskerville, Tracey, Nisbett, Janelle, Morton, Adam, Teasdale, Stephanie, D'Silva, Neisha, Barrett, Helen, Jones, Timothy, Couper, Jennifer, Donaghue, Kim, Isbel, Nicole, Johnson, David W., Donnellan, Leigh, Deo, Permal, Akison, Lisa K., Moritz, Karen M. and O'Moore-Sullivan, Trisha (2021). Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. Scientific Reports, 11 (1) 9422, 9422. doi: 10.1038/s41598-021-88786-4 |
|
2021 Journal Article The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition)Zhuang, Aowen, Yap, Felicia Y. T., Borg, Danielle J., McCarthy, Domenica, Fotheringham, Amelia, Leung, Sherman, Penfold, Sally A., Sourris, Karly C., Coughlan, Melinda T., Schulz, Benjamin L. and Forbes, Josephine M. (2021). The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). Endocrinology, Diabetes and Metabolism, 4 (3) e00278, e00278. doi: 10.1002/edm2.278 |
|
2020 Journal Article Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetesLe Bagge, Selena, Fotheringham, Amelia K., Leung, Sherman S. and Forbes, Josephine M. (2020). Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes. Medicinal Research Reviews, 40 (4) med.21654, 1200-1219. doi: 10.1002/med.21654 |
|
2016 Journal Article Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesisLeung, Sherman S., Forbes, Josephine M. and Borg, Danielle J. (2016). Receptor for advanced glycation end products (RAGE) in type 1 diabetes pathogenesis. Current Diabetes Reports, 16 (10) 100, 100. doi: 10.1007/s11892-016-0782-y |
